Google Trends: How Many People Are Searching for a Female Viagra?

Little pink pill (Stuff NZ)

Little pink pill (Stuff NZ)

Hot on the heels of the news that a female Viagra is edging closer to public consumption, I wanted to see how often U.S. Internet users (which would be basically everyone) were searching for information related to female Viagra. I used “2004-present” as my timeframe.

First, here’s how often “female viagra” (red line) against “viagra” (blue line):

Google Trends: 'Female Viagra' vs. 'Viagra,' U.S. 2004-Present

Google Trends: ‘Female Viagra’ vs. ‘Viagra,’ U.S. 2004-Present

As you can see, there’s a lot less searching for the former term versus the latter.

Now, let’s look at “female Viagra” on its own:

Google Trends: 'Female Viagra,' U.S. 2004-Present

Google Trends: ‘Female Viagra,’ U.S. 2004-Present

It’s hard to ignore that huge spike at the end of the timeframe. That occurred this month. It’s no coincidence: Sprout Pharmaceuticals announced that their female desire pill Flibanserin/ADDYI was recommended for Food & Drug Administration (FDA) approval on Jun. 5th.

Flibanserin/ADDYI will treat women with low libidos, known medically as hypoactive sexual desire disorder (HSDD). I wanted to see how common Google searches for low sex drives appeared.

First, I searched “low sex drive in women,” which was the first specific option Google autofilled for me:

Google Trends: 'Low Sex Drive in Women,' U.S. 2004-Present

Google Trends: ‘Low Sex Drive in Women,’ U.S. 2004-Present

Interesting. It appears that the term hit its peak (ha) around a spike in 2011, and then crested in 2013. It’s dipped since then, but is starting to come back up. (Also, I’d love to know what happened in 2007.)

But let’s put this in context. Here’s “low sex drive in women” (blue line) versus “low sex drive” (red line):

Google Trends: 'Low Sex Drive in Women' vs. 'Low Sex Drive,' U.S. 2004-Present

Google Trends: ‘Low Sex Drive in Women’ vs. ‘Low Sex Drive,’ U.S. 2004-Present

It’s interesting that the female-specific searches don’t make up that much of the overall searches.

Now let’s find out how many men are searching for information on low desire. Here’s “low sex drive in women” (blue line) versus “low sex drive in men” (red line):

Google Trends: 'Low Sex Drive in Women' vs. 'Low Sex Drive in Men,' U.S. 2004-Present

Google Trends: ‘Low Sex Drive in Women’ vs. ‘Low Sex Drive in Men,’ U.S. 2004-Present

OK, now we can see that low libidos in women are an issue, insofar as they’re being Googled.

So a lot of people (we could probably reasonably assume women) are searching for information on low sex drives in women. But how many are searching for a solution? Maybe a cure, call it “female viagra” (red line)?

Google Trends: 'Low Sex Drive in Women' vs. 'Female Viagra,' U.S. 2004-Present

Google Trends: ‘Low Sex Drive in Women’ vs. ‘Female Viagra,’ U.S. 2004-Present

Holy shit, this is amazing. Sure, users are searching for (presumably) information on women having low sex drives, but they’re searching a lot more for a solution. At no point in this graph are there more searches for “low sex drive in women” than there are for “female viagra.” Also, note how the “female viagra” searches spike at the end, halfway through 2015. As noted above, that’s when Sprout announced their “little pink pill.”

Conclusion:

The evidence here points to the fact that people are actively searching for solutions to cure women’s low sex drives. This certainly warrants a female Viagra pill to be brought to market, but why the hell wasn’t this developed sooner?!

Sprout Pharmaceuticals’ Female Viagra Closer to Becoming Publicly Available

The experimental drug flibanserin, made by Sprout Pharmaceuticals, is at the center of a regulatory controversy.

The experimental drug flibanserin, made by Sprout Pharmaceuticals, is at the center of a regulatory controversy.

Sprout Pharmaceuticals has developed what they’re calling the Viagra for women. The new drug, named Flibanserin, purports to treat hypoactive sexual desire disorder (low sex drive, in other words) in pre-menopausal women. So far, $50M has been raised in preparation for the drug’s launch, and the Food & Drug Administration (FDA) has approved its benefits/risk profile.

The drug, now known as ADDYI, has had a long road thus far:  The drug was first rejected in 2010, when it was determined that the risks outweighed the dubious (at the time) benefits. Sprout began working on the drug in 2011, after being sold by the drug’s initial developer Boehringer Ingelheim. In December 2013, the FDA had rejected the drug for the second time.

In February 2014, the FDA wanted to see more tests done, specifically how the drug behaved when used with other medications. (Almost 10% of women taking the pill reported sleepiness during the trial.) The company resubmitted New Drug Application (NDA) this past February. The “little pink pill” was approved by an FDA advisory committee (done one step before final FDA approval), provided that more safety restrictions were added.

So far, Flibanserin/ADDYI has been tested on 11K+ women, and claims to be the “one of the most studied women’s health products in history.” Here’s what Sprout found after some recent trials:

In three 24-week randomized Phase 3, six-month, double-blind, placebo-controlled, parallel-group North American studies of premenopausal women with a mean age of 36 years, ADDYI consistently demonstrated a highly statistically significant difference over placebo on three key endpoints, including increase in sexual desire, decrease in distress from the loss of sexual desire and increase in the frequency of satisfying sex. Women treated with ADDYI showed significant improvements at every point of measurement in all pivotal clinical trials, with benefits seen as early as four weeks and sustained over the 24-week treatment period.

It’s too early to know when the drug will hit the public market. But it’ll be interesting to see how it performs (haha).